Would you continue cemiplimab adjuvantly, following resection of initially unresectable cutaneous squamous cell carcinoma treated with downstaging immunotherapy?

This is a challenging question because, as you know, we have no randomized data to address it. I generally do not continue immune checkpoint therapy after resection of SCC skin. However, given the adjuvant data in melanoma and the high efficacy of anti-PD1 in skin SCC, I do think it is reasonable to...

I would not continue cemiplimab or pembrolizumab in the adjuvant setting since there is no current data to support this practice. However, I would consider adjuvant radiation based on the degree of pathologic response to neoadjuvant therapy. Adjuvant radiation is often considered for CSCC with certa...

First, if the cutaneous squamous cell carcinoma is not resectable, a neoadjuvant approach should be used (Brockwell et al., PMID 36686737). If a tumor looking resectable has been surgically removed but the surgery is an R1 or R2 resection, then additional treatment is needed. If the tumor is an R0 r...

I would consider immunotherapy based on the decision regarding adjuvant radiation therapy. I would discuss the case in our multidisciplinary group and if the decision was to proceed with adjuvant radiation, based on the currently available data I would not continue immunotherapy. However, if the dec...

I would continue cemiplimab adjuvantly (not pembrolizumab adjuvantly, as the KEYNOTE-630 trial was negative), if patients' post-resection path showed high-risk features for recurrence (i.e., positive margin, perineural invasion, extracapsular extension, T4 lesions, etc.), as defined in the C-POST tr...